Develops cancer drug candidates for people with lung, ovarian and other cancers.
10-K for FY2025, filed Mar 12, 2026
Whitehawk sold FYARRO to specialty distributors and a specialty pharmacy; product sales were counted when those buyers obtained the drug. It later sold the FYARRO business.
10-K for FY2025, filed Mar 12, 2026
$7.1M
10-K for FY2025, filed Mar 12, 2026
$7.1M ↗
Whitehawk sold FYARRO to specialty distributors and a specialty pharmacy; government and other entities bought through those channels at discounted prices.
10-K for FY2025, filed Mar 12, 2026
10-K for FY2025, filed Mar 12, 2026
For the year ended December 31, 2025, two customers represented 37% and 60% of the Company's revenue. For the year ended December 31, 2024…View ↗
No. It lost $20.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$21.2MView ↗
8-K, filed May 21, 2026
On May 21, 2026, Whitehawk Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, (i) the expansion of…View ↗
Growing. Revenue grew 6.4x in 4 years, from $1.1M in FY2021 to $7.1M in FY2025, about 59% a year.
From FYARRO to ADC candidates
Earlier, Whitehawk focused on developing and commercializing FYARRO, an albumin-bound sirolimus treatment for cancers involving mTOR pathway alterations. The latest report focuses on developing licensed antibody-drug conjugates for cancers, rather than commercializing FYARRO.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 12, 2026In December 2024, we entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai…View ↗
These in-licensed assets originated through the collaborative efforts of WuXi Biologics, a leading global contract research, development…View ↗
On December 19, 2024, we entered into a Stock Purchase Agreement (the “Divestiture Agreement”) with KAKEN INVESTMENTS INC., a Delaware…View ↗
Competes with AbbVie, Daiichi Sankyo, Day One Biopharmaceuticals, Eli Lilly, Genmab, GlaxoSmithKline, Gilead, Kelun, Mersana, Sanofi, Roche, Pfizer, Zymeworks, Ideaya, and Biocytogen
10-K for FY2025, filed Mar 12, 2026Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we…View ↗
Loading...